Table 6.
Comparison of clinical and treatment-related parameters between the L and S groups in CPM cohort
| Variable | S Group (n = 42) | L Group (n = 62) | χ2 | P |
|---|---|---|---|---|
| Surgery type | 1.024 | 0.599 | ||
| Local excision | 4 (9.52%) | 8 (12.9%) | ||
| Radical excision | 25 (59.52%) | 40 (64.52%) | ||
| Amputation | 13 (30.95%) | 14 (22.58%) | ||
| SAP level | 3.675 | 0.055 | ||
| Normal | 15 (35.71%) | 34 (54.84%) | ||
| High | 27 (64.29%) | 28 (45.16%) | ||
| LDH level | 5.067 | 0.024 | ||
| Normal | 17 (40.48%) | 39 (62.9%) | ||
| High | 25 (59.52%) | 23 (37.1%) | ||
| Radiation | 4.148 | 0.042 | ||
| Yes | 7 (16.67%) | 2 (3.23%) | ||
| No | 35 (83.33%) | 60 (96.77%) | ||
| Histology | 5.58 | 0.134 | ||
| Osteoblastic | 34 (80.95%) | 40 (64.52%) | ||
| Chondroblastic | 5 (11.9%) | 7 (11.29%) | ||
| Fibroblastic | 2 (4.76%) | 6 (9.68%) | ||
| Teleangiectatic | 1 (2.38%) | 9 (14.52%) |
S: Short survival; L: Long survival; CPM: Cisplatin, paclitaxel, and high-dose methotrexate; PMS: SAP: Serum alkaline phosphatase; LDH level: Lactate Dehydrogenase.